The amount raised by private companies in November was again bolstered by two large investment rounds that shored-up an otherwise disappointing month for the private sector, a Scrip analysis has fou
Already hit hard by a difficult regulatory and reimbursement climate, the pace of venture investing in biotechnology has slowed to a crawl because of the global financial crisis. How bad is it, and wh
Genomic content providers like Incyte Genomics Inc. and Celera Genomics Group have packed up their databases and moved downstream into drug development. Despite their proximity to profitability,
Proteomics is hot; genomics is not. We interview the top players to understand how they're dealing with the climatic change. by Roger Longman Biotechnology is a world of continuously changing scientif